Pharmaceutical composition for treating pet constipation as well as preparation method and application thereof

Abstract

The invention discloses a pharmaceutical composition for treating pet constipation and a preparation method and application thereof.The pharmaceutical composition is prepared from raw material medicine, auxiliaries and purified water, and the raw material medicine is prepared from, by mass, 8-12 parts of immature bitter orange, 6-10 parts of malt, 6-10 parts of aloe, 4-10 parts of honey and 10-15 parts of liquorice; the auxiliary agent comprises 0.4-2 parts by mass of amidated pectin, 0.5-2 parts by mass of gelatin and 0.5-1 part by mass of sodium alginate; the purified water accounts for 80-110 parts by mass. The pharmaceutical composition disclosed by the invention can be used for effectively treating constipation of pets, and the prepared suspension has the advantages of good stability, good redispersibility, good palatability and the like.

Description

Technical Field

[0001] The invention relates to the technical field of veterinary drugs, and in particular to a pharmaceutical composition for treating pet constipation, and a preparation method and application thereof. Background Art

[0002] Usually, pets eat dry, hard or indigestible food for a long time or have bad eating habits, lack of sufficient dietary fiber and water, which will lead to slow gastrointestinal motility, weakened digestive function, and long-term accumulation of food residues in the intestines, causing constipation. Cats are particularly prone to constipation due to excessive hair ingestion, which forms hairballs in the gastrointestinal tract. Currently, there are relatively few drugs for pet constipation. Lactulose is a commonly used drug, but lactulose often causes vomiting. There is an urgent need to develop new drugs for treating pet constipation. Summary of the invention

[0003] In order to solve the problems existing in the prior art, the technical solution of the present invention is as follows:

[0004] In a first aspect, the present invention provides a pharmaceutical composition for treating pet constipation, comprising a raw material drug, an adjuvant and purified water, wherein the raw material drug comprises 8-12 parts by mass of Citrus aurantium, 6-10 parts by mass of malt, 4-8 parts by mass of aloe, 4-10 parts by mass of honey and 10-15 parts by mass of licorice.

[0005] In a second aspect, the present invention provides use of the above-mentioned pharmaceutical composition for treating pet constipation in the preparation of a veterinary preparation, wherein the veterinary preparation is one of a capsule, a suspension and a cream.

[0006] In a third aspect, the present invention provides a method for preparing a suspension of a pharmaceutical composition for treating pet constipation, comprising the following steps:

[0007] (1) mixing raw materials of Citrus aurantium, malt, aloe vera and liquorice according to weight parts, crushing to obtain a first mixture, and adding 40-60 weight parts of purified water under a first ultrasonic condition;

[0008] The first ultrasonic conditions include ultrasonic frequency of 15-20 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 35-50° C., and ultrasonic time of 30 s-2 min;

[0009] (2) adding honey, amidated pectin, gelatin, sodium alginate and isoascorbic acid according to mass fractions into the remaining amount of purified water under a second ultrasonic condition to obtain a second mixture;

[0010] The second ultrasonic conditions include ultrasonic frequency of 10-15 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 25-35° C., and ultrasonic time of 20 s-2 min;

[0011] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25-30° C. to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0012] The third ultrasonic condition includes ultrasonic frequency of 15-20 kHz, ultrasonic power of 200-300 W, ultrasonic temperature of 40-50° C., and ultrasonic time of 30 s-1 min.

[0013] In a fourth aspect, the present invention provides a suspension of a pharmaceutical composition for treating pet constipation prepared by the method described above.

[0014] The beneficial effects of the present invention include at least:

[0015] (1) The pharmaceutical composition of the present invention adopts a reasonable formulation and can effectively treat pet constipation, especially pet constipation caused by food accumulation and / or hairballs formed by the accumulation of accidentally ingested hair.

[0016] (2) The suspension of the present invention uses an auxiliary agent having multiple properties at the same time, and the preparation method adopts ultrasonic dispersion treatment, so that the suspension has the advantages of good stability, good redispersibility, good palatability, etc.

[0017] The features and advantages of the present invention will be described in detail in the following detailed description. DETAILED DESCRIPTION

[0019] The endpoints of the scope disclosed in the present invention and any value are not limited to this accurate scope or value, and these scopes or values ​​should be understood as comprising values ​​close to these scopes or values. For numerical range, between the endpoint values ​​of each scope, between the endpoint values ​​of each scope and a separate point value, and between separate point values, can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be considered as specifically disclosed in this article. In the description of the application, unless otherwise stated, the meaning of similar words such as "multiple / multiple" is two / kinds or more than two / kinds. In addition, the terms "include", "comprise" and any distortion thereof are intended to cover non-exclusive inclusions.

[0020] In a first aspect, the present invention provides a pharmaceutical composition for treating pet constipation, comprising a raw material drug, an adjuvant and purified water, wherein the raw material drug comprises 8-12 parts by mass of Citrus aurantium, 6-10 parts by mass of malt, 4-8 parts by mass of aloe, 4-10 parts by mass of honey and 10-15 parts by mass of licorice.

[0021] In the present invention, the raw materials all meet the requirements of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine.

[0022] In the present invention, adjuvants can be understood as pharmaceutical excipients.

[0023] In some preferred embodiments, the auxiliary agent includes 0.4-2 parts by mass of amidated pectin, 0.5-2 parts by mass of gelatin and 0.5-1 parts by mass of sodium alginate; 80-110 parts by mass of purified water; and 0.6-2 parts by mass of antioxidant to prepare a suspension.

[0024] In some more preferred embodiments, the antioxidant is selected from at least one of isoascorbic acid, ascorbyl palmitate and vitamin E.

[0025] In some preferred embodiments, the raw materials include 8-10 parts by mass of Citrus aurantium, 6-8 parts by mass of malt, 4-6 parts by mass of aloe, 6-10 parts by mass of honey, and 10-12 parts by mass of licorice; the auxiliary agents include 1-2 parts by mass of amidated pectin, 1-1.5 parts by mass of gelatin, and 0.8-1 parts by mass of sodium alginate; the purified water is 90-100 parts by mass; and the antioxidant is 0.8-1.5 parts by mass.

[0026] In some preferred embodiments, the amidation degree of the amidated pectin is 15%-20%, and the number average molecular weight is 40,000-60,000; and / or the number average molecular weight of the gelatin is 20,000-80,000.

[0027] In a second aspect, the present invention provides use of the above-mentioned pharmaceutical composition for treating pet constipation in the preparation of a veterinary preparation, wherein the veterinary preparation is one of a capsule, a suspension and a cream.

[0028] In some preferred embodiments, the veterinary preparation is in the form of a suspension.

[0029] In a third aspect, the present invention provides a method for preparing a suspension of a pharmaceutical composition for treating pet constipation, comprising the following steps:

[0030] (1) mixing raw materials of Citrus aurantium, malt, aloe vera and liquorice according to weight parts, crushing to obtain a first mixture, and adding 40-60 weight parts of purified water under a first ultrasonic condition;

[0031] The first ultrasonic conditions include ultrasonic frequency of 15-20 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 35-50° C., and ultrasonic time of 30 s-2 min;

[0032] (2) adding honey, amidated pectin, gelatin, sodium alginate and isoascorbic acid according to mass fractions into the remaining amount of purified water under a second ultrasonic condition to obtain a second mixture;

[0033] The second ultrasonic conditions include ultrasonic frequency of 10-15 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 25-35° C., and ultrasonic time of 20 s-2 min;

[0034] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25-30° C. to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0035] The third ultrasonic condition includes ultrasonic frequency of 15-20 kHz, ultrasonic power of 200-300 W, ultrasonic temperature of 40-50° C., and ultrasonic time of 30 s-1 min.

[0036] In some preferred embodiments, in order to obtain a suspension with better stability, redispersibility and palatability, in step (1), the first ultrasonic conditions include ultrasonic frequency 18-20 kHz, ultrasonic power 180-200 W, ultrasonic temperature 40-50° C., and ultrasonic time 1 min-2 min.

[0037] In some preferred embodiments, in order to obtain a suspension with better stability, redispersibility and palatability, in step (2), the second ultrasonic conditions include ultrasonic frequency 10-12 kHz, ultrasonic power 120-150 W, ultrasonic temperature 30-35° C., and ultrasonic time 50 s-1.5 min.

[0038] In some preferred embodiments, in order to obtain a suspension with better stability, redispersibility and palatability, in step (3), the third ultrasonic condition includes an ultrasonic frequency of 18-20 kHz, an ultrasonic power of 260-290 W, an ultrasonic temperature of 45-50° C., and an ultrasonic time of 40 s-1 min.

[0039] In a fourth aspect, the present invention provides a suspension of a pharmaceutical composition for treating pet constipation prepared by the method described above.

[0040] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the examples. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention. The tests not specified in the following examples are all carried out according to the conditions of the 2020 edition of the Chinese Veterinary Pharmacopoeia, and the chemicals are all commercially available.

[0041] In the following examples and comparative examples, the amidated pectin has an amidation degree of 15%-20% and a number average molecular weight of 40,000-60,000; the number average molecular weight of gelatin is 20,000-80,000.

[0042] Example 1

[0043] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0044] (1) mixing 10 g of raw materials of Citrus aurantium, 6 g of malt, 5 g of aloe vera and 10 g of liquorice, crushing to obtain a first mixture, and adding 50 g of purified water under a first ultrasonic condition;

[0045] The first ultrasonic condition includes an ultrasonic frequency of 18 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 45° C., and an ultrasonic time of 1 min;

[0046] (2) adding 8 g of honey, 1.5 g of amidated pectin, 1 g of gelatin, 0.8 g of sodium alginate and 1.5 g of isoascorbic acid to 50 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0047] The second ultrasonic condition includes an ultrasonic frequency of 12 kHz, an ultrasonic power of 150 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 1 min;

[0048] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0049] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 280 W, an ultrasonic temperature of 45° C., and an ultrasonic time of 50 s.

[0050] Example 2

[0051] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0052] (1) 8 g of raw materials of Citrus aurantium, 6 g of malt, 5 g of aloe vera and 10 g of liquorice were mixed and crushed to obtain a first mixture, and then added to 60 g of purified water under a first ultrasonic condition;

[0053] The first ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 180 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 30 s;

[0054] (2) adding 6 g of honey, 1 g of amidated pectin, 1.5 g of gelatin, 1 g of sodium alginate and 1 g of isoascorbic acid to 40 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0055] The second ultrasonic condition includes an ultrasonic frequency of 10 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0056] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0057] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 30 s.

[0058] Example 3

[0059] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0060] (1) mixing 12 g of raw materials of Citrus aurantium, 10 g of malt, 4 g of aloe vera and 4 g of liquorice, crushing to obtain a first mixture, and adding 40 g of purified water under a first ultrasonic condition;

[0061] The first ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 100 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0062] (2) adding 10 g of honey, 2 g of amidated pectin, 1 g of gelatin, 0.8 g of sodium alginate and 2 g of isoascorbic acid to 60 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0063] The second ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 180 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 20 s;

[0064] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0065] The third ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 300 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 1 min.

[0066] Example 4

[0067] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0068] (1) mixing 11 g of raw materials of Citrus aurantium, 7 g of malt, 6 g of aloe vera and 9 g of liquorice, crushing to obtain a first mixture, and adding 50 g of purified water under a first ultrasonic condition;

[0069] The first ultrasonic condition includes an ultrasonic frequency of 18 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 50° C., and an ultrasonic time of 2 min;

[0070] (2) adding 9 g of honey, 1.5 g of amidated pectin, 1.5 g of gelatin, 1 g of sodium alginate and 2 g of isoascorbic acid to 60 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0071] The second ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0072] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0073] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 50° C., and an ultrasonic time of 30 s.

[0074] Example 5

[0075] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0076] (1) mixing 10 g of raw materials of Citrus aurantium, 10 g of malt, 7 g of aloe vera and 13 g of liquorice, crushing to obtain a first mixture, and adding it to 60 g of purified water under a first ultrasonic condition;

[0077] The first ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 30 s;

[0078] (2) adding 9 g of honey, 1 g of amidated pectin, 1.5 g of gelatin, 0.8 g of sodium alginate and 1.5 g of isoascorbic acid to 50 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0079] The second ultrasonic condition includes an ultrasonic frequency of 12 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 25° C., and an ultrasonic time of 2 min;

[0080] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0081] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 300 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 50 s.

[0082] Example 6

[0083] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0084] (1) Mix 9 g of raw materials of Citrus aurantium, 7 g of malt, 6 g of aloe vera and 12 g of liquorice, grind them to obtain a first mixture, and add 60 g of purified water under a first ultrasonic condition;

[0085] The first ultrasonic condition includes an ultrasonic frequency of 18 kHz, an ultrasonic power of 150 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0086] (2) adding 9 g of honey, 1 g of amidated pectin, 1 g of gelatin, 0.8 g of sodium alginate and 1 g of isoascorbic acid to the remaining amount of purified water under a second ultrasonic condition to obtain a second mixture;

[0087] The second ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0088] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0089] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 300 W, an ultrasonic temperature of 50° C., and an ultrasonic time of 30 s.

[0090] Example 7

[0091] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0092] (1) Mix 8 g of raw materials of Citrus aurantium, 8 g of malt, 6 g of aloe vera and 10 g of liquorice, grind them to obtain a first mixture, and add 50 g of purified water under a first ultrasonic condition;

[0093] The first ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 42° C., and an ultrasonic time of 1 min;

[0094] (2) adding 10 g of honey, 1.5 g of amidated pectin, 1.5 g of gelatin, 1 g of sodium alginate and 2 g of isoascorbic acid to 60 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0095] The second ultrasonic condition includes an ultrasonic frequency of 15 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 35° C., and an ultrasonic time of 2 min;

[0096] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25° C., to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0097] The third ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 300 W, an ultrasonic temperature of 40° C., and an ultrasonic time of 30 s.

[0098] Example 8

[0099] A method for preparing a suspension of a pharmaceutical composition for treating pet constipation comprises the following steps:

[0100] (1) mixing 10 g of raw materials of Citrus aurantium, 8 g of malt, 7 g of aloe vera and 13 g of liquorice, crushing to obtain a first mixture, and adding 60 g of purified water under a first ultrasonic condition;

[0101] The first ultrasonic condition includes an ultrasonic frequency of 20 kHz, an ultrasonic power of 200 W, an ultrasonic temperature of 50° C., and an ultrasonic time of 2 min;

[0102] (2) adding 10 g of honey, 2 g of amidated pectin, 1 g of gelatin, 1 g of sodium alginate and 1.5 g of isoascorbic acid to 50 g of purified water under a second ultrasonic condition to obtain a second mixture;

[0103] The second ultrasonic conditions include ultrasonic frequency of 10-15 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 25-35° C., and ultrasonic time of 20 s-2 min;

[0104] (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25-30° C. to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm;

[0105] The third ultrasonic condition includes ultrasonic frequency of 15-20 kHz, ultrasonic power of 200-300 W, ultrasonic temperature of 40-50° C., and ultrasonic time of 30 s-1 min.

[0106] Comparative Example 1

[0107] The raw material does not include malt, and the other preparation processes are the same as those in Example 1.

[0108] Comparative Example 2

[0109] The raw material does not include honey, and the other preparation processes are the same as those in Example 1.

[0110] Comparative Example 3

[0111] The auxiliary agent does not include amidated pectin, and the other preparation processes are the same as those in Example 1.

[0112] Test Example 1

[0113] 1. Properties

[0114] The appearance of the suspensions prepared in Examples 1-8 was observed and recorded. The observation results showed that the suspensions were all light brown. After standing and stratification, the upper layer of the suspensions prepared in Examples 1-8 of the present invention was a light yellow or light brown transparent liquid, and the lower layer was a light brown or light brown liquid. The comparative examples had no difference in appearance.

[0115] 2. Determination of sedimentation volume ratio

[0116] 50 mL of the suspension prepared by Examples 1-8 of the present invention and Comparative Examples 1-3 was placed in a 50 mL stoppered test tube, shaken vigorously for 1 minute, the starting height H0 of the suspension was recorded, and the height H of the sediment was recorded after standing for 2, 4, 6, 12 h and 1, 3, 5, 7 d, respectively, and the sedimentation volume ratio (F=H / H0) of the suspension was calculated. The sedimentation volume ratios of the suspensions prepared by Examples 1-8 of the present invention were all greater than 0.97, and the sedimentation volume ratios of the suspensions prepared by Comparative Examples 1-3 were less than 0.92.

[0117] 3. Redispersibility

[0118] After the suspensions prepared in Examples 1-8 and Comparative Examples 1-3 were left to stand for 7 days, the measuring cylinders were turned over 1-2 times to restore the state of the suspensions. The redispersibility of the suspensions prepared in Examples 1-8 of the present invention was better than that of Comparative Examples 1-3.

[0119] Test Example 2

[0120] Safety evaluation was conducted by oral acute toxicity test in mice

[0121] In this test example, the experimental subjects are 20 SPF mice, weighing between 20-25g, half of which are male and half are female.

[0122] The suspension prepared in Example 1 was administered orally to SPF mice to measure the LD 50 The test results showed that no mice died and the LD50 of oral administration could not be determined. 50 , which can only indicate the LD50 of the preparation after oral administration 50 >40000mg / kg body weight. According to the result evaluation standard and toxicological evaluation standard of the "Collection of Veterinary Drug Test Technical Specifications", the preparation of the present invention can be judged to be non-toxic. In the maximum dosage test, the drug was administered by gavage 4 times within 16 hours, and each time the drug was administered with the maximum dosage volume for gavage administration to mice. Except for the decrease in water intake and inactivity after administration, the mice were observed to be in good condition within 10 days, without abnormal phenomena or death.

[0123] Test Example 3

[0124] Clinical trial conducted on dogs suffering from constipation in cooperative pet hospitals

[0125] The suspension prepared in Example 1 of the present invention was administered to 60 dogs suffering from constipation for 3 days, 57 dogs were cured, with a cure rate of 95%; 2 dogs were effective, with an effective rate of 3.3%; and 1 dog was ineffective, with an ineffective rate of 1.7%.

[0126] After 5 days of medication, the two effective dogs were cured, with a cure rate of 98.3%, and it was confirmed that the constipation of the one ineffective dog was caused by other diseases.

[0127] In addition, it was observed during the administration process that the suspension prepared by the present invention had good palatability, and no gastrointestinal discomfort and vomiting caused by medication occurred.

[0128] The suspension prepared in Comparative Example 1 was administered for 3 days to treat 60 dogs suffering from constipation, and 24 dogs were cured, with a cure rate of 40%; 6 dogs were effective, with an effective rate of 10%; and 30 dogs were ineffective, with an ineffective rate of 50%. After 5 days of administration, the 6 effective dogs and the 30 ineffective dogs were not cured. It was confirmed that the uncured dogs were all caused by pet constipation due to food accumulation and / or accumulation of hair balls formed by accidentally ingested hair, while the cured dogs were all caused by constipation due to other reasons.

[0129] The suspension prepared in Comparative Example 2 was administered for 3 days to treat 60 dogs suffering from constipation, and 30 dogs were cured, with a cure rate of 50%; 9 dogs were effective, with an effective rate of 15%; and 21 dogs were ineffective, with an ineffective rate of 35%. After 5 days of administration, the 9 effective dogs and the 21 ineffective dogs were not cured. It was confirmed that the uncured dogs were all caused by pet constipation due to food accumulation and / or accumulation of hair balls formed by accidentally ingested hair, while the cured dogs were all caused by constipation due to other reasons.

[0130] The suspension prepared in Comparative Example 3 was administered for 3 days to treat 60 dogs suffering from constipation, and 16 dogs were cured, with a cure rate of 26.7%; 4 dogs were effective, with an effective rate of 6.7%; and 40 dogs were ineffective, with an ineffective rate of 66.7%. After 5 days of administration, the 4 effective dogs and the 40 ineffective dogs were not cured. It was confirmed that the uncured dogs were all caused by constipation of pets due to food accumulation and / or accumulation of hair balls formed by accidentally ingested hair, while the cured dogs were all caused by constipation due to other reasons.

[0131] Test Example 4

[0132] Clinical trial conducted on cats suffering from constipation in cooperating veterinary hospitals

[0133] 60 cats suffering from constipation were treated with the suspension prepared in Example 1 of the present invention for 3 days, 56 cats were cured, with a cure rate of 93.3%; 2 cats were effective, with an effective rate of 3.3%; and 1 cat was ineffective, with an ineffective rate of 1.6%.

[0134] Among the 56 cured cats, 20 were found to have hairballs in their abdomens in advance. 18 cats vomited out the hairballs within 2 days of taking the medicine, and the other 2 cats vomited out the hairballs within 4 days of taking the medicine.

[0135] Furthermore, it was observed during the administration process that the suspension prepared by the present invention had good palatability, and no gastrointestinal discomfort and vomiting caused by taking the medicine occurred.

[0136] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and do not constitute a limitation on the content of the present invention. Although the present invention has been listed in detail through the above embodiments, those skilled in the art can still make various changes in form and details according to the technical contents described in the summary of the invention and the embodiment part, without departing from the spirit and scope of the present invention defined by the attached claims.

Claims

1. A pharmaceutical composition for treating pet constipation, characterized in that: The invention comprises raw materials, auxiliary agents and purified water, wherein the raw materials comprise 8-12 parts by weight of immature bitter orange, 6-10 parts by weight of malt, 4-8 parts by weight of aloe, 4-10 parts by weight of honey and 10-15 parts by weight of liquorice.

2. The pharmaceutical composition for treating pet constipation according to claim 1, characterized in that: The auxiliary agent comprises 0.4-2 parts by weight of amidated pectin, 0.5-2 parts by weight of gelatin and 0.5-1 parts by weight of sodium alginate; 80-110 parts by weight of purified water; and 0.6-2 parts by weight of antioxidant.

3. The pharmaceutical composition for treating pet constipation according to claim 2, characterized in that: The antioxidant is selected from at least one of isoascorbic acid, ascorbyl palmitate and vitamin E.

4. The pharmaceutical composition for treating pet constipation according to claim 2, characterized in that: The raw materials include 8-10 parts by weight of Citrus aurantium, 6-8 parts by weight of malt, 4-6 parts by weight of aloe, 6-10 parts by weight of honey and 10-12 parts by weight of liquorice; The auxiliary agent comprises 1-2 parts by mass of amidated pectin, 1-1.5 parts by mass of gelatin and 0.8-1 parts by mass of sodium alginate; 90-100 parts by mass of purified water; The antioxidant is 0.8-1.5 parts by mass.

5. The pharmaceutical composition for treating pet constipation according to claim 2, characterized in that: The amidation degree of the amidated pectin is 15%-20%, and the number average molecular weight is 40000-60000; and / or the number average molecular weight of the gelatin is 20000-80000.

6. Use of the pharmaceutical composition for treating pet constipation according to any one of claims 1 to 5 in the preparation of veterinary preparations, wherein the veterinary preparation is one of a capsule, a suspension and an ointment.

7. The use according to claim 6, wherein the veterinary preparation is in the form of a suspension.

8. A method for preparing a suspension of a pharmaceutical composition for treating pet constipation, characterized in that: The following steps are involved: (1) mixing raw materials of Citrus aurantium, malt, aloe vera and liquorice according to weight parts, crushing to obtain a first mixture, and adding 40-60 weight parts of purified water under a first ultrasonic condition; The first ultrasonic conditions include ultrasonic frequency of 15-20 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 35-50° C., and ultrasonic time of 30 s-2 min; (2) adding honey, amidated pectin, gelatin, sodium alginate and isoascorbic acid according to mass fractions into the remaining amount of purified water under a second ultrasonic condition to obtain a second mixture; The second ultrasonic conditions include ultrasonic frequency of 10-15 kHz, ultrasonic power of 100-200 W, ultrasonic temperature of 25-35° C., and ultrasonic time of 20 s-2 min; (3) mixing the first mixture and the second mixture evenly under a third ultrasonic condition, cooling to 25-30° C. to obtain a suspension; the particle size distribution of the drug in the suspension is 0.2-3 μm; The third ultrasonic condition includes ultrasonic frequency of 15-20 kHz, ultrasonic power of 200-300 W, ultrasonic temperature of 40-50° C., and ultrasonic time of 30 s-1 min.

9. The method for preparing a suspension of a pharmaceutical composition for treating pet constipation according to claim 8, characterized in that: In step (1), the first ultrasonic conditions include ultrasonic frequency 18-20 kHz, ultrasonic power 180-200 W, ultrasonic temperature 40-50° C., and ultrasonic time 1 min-2 min; and / or In step (2), the second ultrasonic conditions include ultrasonic frequency 10-12 kHz, ultrasonic power 120-150 W, ultrasonic temperature 30-35° C., and ultrasonic time 50 s-1.5 min; and / or In step (3), the third ultrasonic condition includes ultrasonic frequency 18-20 kHz, ultrasonic power 260-290 W, ultrasonic temperature 45-50° C., and ultrasonic time 40 s-1 min.

10. A suspension of a pharmaceutical composition for treating pet constipation prepared by the method of claim 8 or 9.